##  [Statistical Approaches to Establishing Bioequivalence](/index%2ephp/mandate/statistical-approaches-to-establishing-bioequivalence) 

May 26, 2026

The guidance details on below pointers:

1. 1. BE Approaches: Discusses average bioequivalence (ABE), population bioequivalence (PBE), and individual bioequivalence (IBE) approaches.
2. 2. Application Scope: In vivo and in vitro BE studies for INDs, NDAs, ANDAs, and supplements
3. 3. Replaces 1999 Draft: Replaces 1999 draft guidance ""Average, Population, and Individual Approaches to Establishing Bioequivalence""
4. 4. Updated Topics (2022): Missing data and intercurrent events, adaptive design, narrow therapeutic index drugs, highly variable drugs.
5. 5. Missing Data: Outlines ICH estimands concept; advises methods to minimize missing data to avoid bias, loss of precision/power.
6. 6. Other aspects include novel methodologies, highly variable drug products, etc.



[Consult Now](/webform/consult%0A?url=https://preprod.freyrsolutions.com/index%2ephp/markdownify/node/13548)



Source

[https://www.fda.gov/regulatory-information/search-fda-guidance-documents/statis…](https://www.fda.gov/regulatory-information/search-fda-guidance-documents/statistical-approaches-establishing-bioequivalence)

 

 

Select Mandate HA

[USFDA](/index%2ephp/mandate-by-ha/usfda)

 

Select Mandate Function

[Regulatory Affairs](/index%2ephp/mandate-by-function/regulatory-affairs)